Skip to content

Bioventus BVS Goodwill

Goodwill at other companies

Stryker logo
StrykerSYK
$19.19B+0.5%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$194.93M0.0%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$9.93B+10.5%
Medtronic logo
MedtronicMDT
$42.59B+2.0%
Globus Medical logo
Globus MedicalGMED
$1.44B+0.4%
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
$28.77M0.0%

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's goodwill?
Bioventus (BVS) reported goodwill of $7.46M in Q1 2026.
How has Bioventus's goodwill changed year-over-year?
Bioventus's goodwill decreased by 0.0% year-over-year, from $7.46M to $7.46M.
What is the long-term trend for Bioventus's goodwill?
Over 5 years (2020 to 2025), Bioventus's goodwill has grown at a -31.6% compound annual growth rate (CAGR), from $49.8M to $7.46M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.